Microbiota-derived corisin accelerates kidney fibrosis by promoting cellular aging.
Summary
This translational study identifies corisin as a microbiota-derived peptide that drives diabetic kidney fibrosis. Elevated corisin correlates with disease severity in humans, and monoclonal anti-corisin therapy reduces nephropathy in diabetic mice, implicating cellular senescence, EMT, and apoptosis as mechanisms.
Key Findings
- Serum corisin is markedly elevated in diabetic CKD and correlates with disease stage and renal function decline.
- Anti-corisin monoclonal antibody significantly attenuates nephropathy severity and fibrosis in diabetic mice.
- Corisin binds human serum albumin, potentially enhancing renal accumulation, and induces cellular senescence, EMT, and apoptosis in kidney cells.
Clinical Implications
Corisin may serve as a biomarker for risk stratification in diabetic kidney disease and as a therapeutic target; anti-corisin biologics warrant early-phase clinical development.
Why It Matters
Reveals a novel, targetable microbiota-derived driver of diabetic kidney disease with therapeutic proof-of-concept using a monoclonal antibody.
Limitations
- Human sample size and cohort characteristics were not detailed, limiting generalizability and confounder assessment.
- Therapeutic efficacy demonstrated only in preclinical models; safety and translational dosing remain unknown.
Future Directions
Validate corisin as a prognostic biomarker in prospective diabetic cohorts; initiate first-in-human studies of anti-corisin therapeutics; delineate upstream microbial sources and host regulation of corisin.
Study Information
- Study Type
- Case-control
- Research Domain
- Pathophysiology
- Evidence Level
- III - Translational case-control human data with supportive preclinical interventional models.
- Study Design
- OTHER